ReviewAdvances in experimental medicine and biology2026
Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GD2, a tumor-associated carbohydrate antigen, has been validated as a promising immunotherapeutic target for the treatment of high-risk neuroblastoma. Historically, cancer therapies have largely focused on protein targets. However, the FDA approval of dinutuximab, a GD2-specific monoclonal antibody, in 2015 marked a significant shift by establishing carbohydrates as viable therapeutic targets. Since then, anti-GD2 has become a key component of the standard treatment regimen for high-risk neuroblastoma. Beyond neuroblastoma, GD2 is also expressed in several other malignancies, including melanoma, glioma, small cell lung cancer, and sarcoma. A wide array of therapeutic strategies targeting GD2 has been developed, encompassing murine, chimeric, and humanized antibodies; bispecific antibodies; immunocytokines; chimeric antigen receptor (CAR)-T and CAR natural killer T (NKT) cells; and vaccine-based approaches. A thorough understanding of the strengths and limitations of each of these modalities is essential to inform the design of more effective combination therapies and to improve outcomes for patients with GD2-expressing tumors.
Indexed as
Identifiers
41917415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.